Recently, a more complete understanding of the pharmacodynamics of aminoglycosides has been recognized, indicating that this class of antibiotics exhibits both concentration-dependent bactericidal activity and a postantibiotic effect. This pharmacodynamic information, along with better knowledge of the mechanisms responsible for aminoglycoside toxicity, established the foundation for once-daily aminoglycoside dosing regimens. This new approach to aminoglycoside dosing appears to be safe, efficacious, and cost-effective, resulting in its increasing popularity in clinical practice.
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Although aminoglycoside antibiotics have been used sucat the binding site for a finite period of time [5] . The presence cessfully for ú50 years [1] , recent data suggest that the convenof the antibiotic prohibits normal biochemical reactions and, tional dosing approach has not optimized bacterial killing.
therefore, the organism dies. The concentration needed to ocThese recent observations, together with a more complete uncupy the critical number of sites necessary for this to occur is derstanding of pharmacodynamics, have led to the application not known. However, an easily measured and probably proporof new aminoglycoside dosing regimens [2, 3] . In this report tional concentration, such as the MIC or the MBC, is used in we discuss the pharmacodynamics of aminoglycosides and the its place. new dosing strategies for this class of antibiotics.
It is also important to realize that the concentration of drug The in vitro antimicrobial spectrum of activity of the aminoin the area of binding sites is controlled by drug concentration glycosides includes a broad range of aerobic gram-negative in the media in which bacteria reside, usually interstitial-like bacilli, many staphylococci, and certain mycobacteria [4] .
fluid. Antibiotics in such fluids have generally been found to Aminoglycosides exert their bactericidal effects by irreversibly rapidly become in equilibrium with the blood; therefore, antibibinding to the 30S ribosomal subunit of susceptible bacteria, otic blood (serum, plasma) concentrations are an important which results in the inhibition of protein synthesis [4] . An parameter in bactericidal activity. Bactericidal activity is thereenergy-and oxygen-dependent transport mechanism is required fore a function of antibiotic concentration in the serum and the for aminoglycosides to penetrate the outer bacterial membrane duration of time that antibiotic exists in the body. of susceptible bacteria [4] . It is for this reason that this class
In pharmacodynamic terms, one can say that bactericidal of antibiotics demonstrates poor activity against anaerobes and activity is a function of the time that serum concentrations has decreased ability to penetrate the bacteria within abscesses remain above some critical value, i.e., the MIC. Pharmacokinetthat may have limited oxygen.
ically, the product of concentration and time is termed the area In general, the aminoglycosides are clinically used in the under the serum-time curve (AUC), and therefore it is also true treatment of documented or suspected gram-negative infections that bactericidal activity is a function of the AUC. Fortunately, and are often combined with b-lactams for extrarenal infecthis relationship can be simplified. tions. In addition, aminoglycosides are used in combination For concentration-independent-killing drugs such as b-lacwith other antibiotics for synergy in the treatment of difficult tams, the rate of bacterial killing is constant once a value of infections, such as enterococcal endocarditis.
Ç2 -4 times the MIC is reached. Under these conditions, the contribution made by the concentration component of the AUC Bactericidal Activity (Cp 1 t) is negligible and the pharmacokinetic relationship to For antibiotics to kill bacteria, they must interact with a bacterial killing is just a function of the time that concentrations binding site, occupy a critical number of these sites, and remain remain above the MIC. As a result, the goal of therapy with these agents should be to maintain their concentration above the MIC against the infecting pathogen for as long as possible drug is no longer important to the killing process, and the hours has been reported in the literature for aminoglycosides [7, 24] . eradication of bacteria is only a function of drug concentration.
Concentration-dependent activity of aminoglycosides has been demonstrated in several in vitro and in vivo animal studies Adaptive and Selective Resistance [6 -13] . While the exact concentration necessary for this simplification to occur is not known, a value of 10 times the MIC Adaptive resistance is the decreased drug uptake that occurs seems to be a generally accepted ratio of peak serum concentrain bacteria that survive an initial, suboptimal aminoglycoside tion to MIC; this will be discussed in more detail below. When dose [29] . This process has been shown to occur in several in the ratio is less than Ç10, then the time of exposure of bacteria vitro and animal studies reported in the literature [11, 30, 31] . to drug cannot be ignored, and the entire AUC must be considOne study showed that once-daily dosing of amikacin, in comered in pharmacodynamic evaluation. Therefore, the goal of parison with q12h dosing, helped maintain its bactericidal actherapy with aminoglycosides is to optimize peak concentrativity against isolates of Pseudomonas aeruginosa [32] . Thus, tions by employing the highest possible dose consistent with drug regimens that allow for longer drug-free intervals should toxicological considerations.
help protect the bactericidal activity of aminoglycosides by In accordance with these data, clinical studies have shown decreasing adaptive resistance. High-dose aminoglycoside therthat higher aminoglycoside peak concentrations have been asapy, if properly designed (i.e., with peak-to-MIC ratios of sociated with increased survival and enhanced therapeutic re-Ç10), helps suppress the survival of high-MIC mutants within sponse in the treatment of gram-negative bacteremia and pneua population of generally susceptible organisms. The lack of monia [14 -17] . One clinical study demonstrated a relationship emergence of resistant organisms during therapy is a major between serum aminoglycoside concentrations and the MIC of advantage to high-dose aminoglycoside regimens. the organism [6] . These investigators found a graded doseresponse effect between an increasing maximal peak concentration/MIC ratio and clinical response [6] .
Aminoglycoside Therapy with Extended Dosing Intervals Other studies have shown that the peak aminoglycoside concentration/MIC ratio needs to be at least between 8:1 and 10:1
With regard to the pharmacodynamic profile of aminoglycosides, several advantages of using extended dosing interin order to maximize the bactericidal effects of these drugs [9 -11, 18] . In addition to optimizing bactericidal activity, the vals are readily apparent. As stated previously, giving aminoglycosides as a single daily dose, as opposed to using peak/MIC ratio of 10:1 was associated with a decrease in the selection and regrowth of resistant subpopulations present in conventional dosing strategies, provides the opportunity to maximize the peak concentration/MIC ratio and the resultant the initial inoculum [9] . bactericidal activity. In addition, the PAE may also allow for longer periods of bacterial suppression during the dosing interval. Lastly, this aminoglycoside dosing approach may Postantibiotic Effect prevent the development of bacterial resistance and reduce the potential for toxicity [33] . The postantibiotic effect (PAE) is defined as the persistent suppression of bacterial growth after limited exposure of organOnce-daily aminoglycoside (ODA) therapy has been evaluated in several large clinical studies, some with a total study isms to an antibiotic [19] [20] [21] . Several factors are known to influence the presence and duration of the PAE. They include population of §100 patients [34 -43]. Of those that compared ODA with multidose aminoglycoside regimens by study detype of organism, class and concentration of antibiotic, duration of antimicrobial exposure, and antimicrobial combinations [21- sign, ODA was shown to be as efficacious or superior to traditional dosing for the treatment of a wide variety of infections 23]. Drug-induced nonlethal damage is the probable mechanism of the PAE of aminoglycosides and b-lactams. Therefore, nonle-[34 -41]. Toxicity evaluations showed that there were no differences between the two dosing methods with regard to nephrothal damage by aminoglycosides would be caused by the irreversible binding to bacterial ribosomes [22, 23] 37, 41, 42] . In addition, two of the studies were hibit a PAE on both gram-positive and gram-negative organisms [7, 11, 19 -26] . A definite correlation between increased of neutropenic patients and showed that ODA therapy maintained its efficacy [39, 40] . Furthermore, a recent report from concentration of aminoglycoside and longer duration of the PAE has been reported [24, 26] . It has been shown in in vitro one hospital using an ODA protocol (7 mg/kg dosing for gentamicin or tobramycin) indicates that no adverse outcomes and animal studies that the duration of the PAE can vary with subsequent doses [27, 28] treated patients were ú70 years of age and 37% of all patients underwent therapy for §6 days, among a population of 2,184 At Hartford Hospital (Hartford, CT), ODA therapy has been used since October 1992 [3], for ú3,500 patients. A fixed iv patients [3]. The incidence of nephrotoxicity was lower with ODA than it has been historically (1.2% vs. 3% -5%). Of the dose of 7 mg/kg is utilized, and either a special nomogram and a single serum level determination or a creatinine clearance patients treated, two had clinical evidence of vestibular toxicity while hospitalized. calculation determines the dosing interval. This dose was selected on the basis of pharmacokinetic modeling designed to Of the 59 patients who were prospectively followed, all receiving ODA therapy for extrapulmonary infections were obtain a target peak concentration of 20 mg/mL. This concentration was selected since it is 10 times the average MIC clinically and microbiologically cured [3] . Clinical cure was noted in 86% (25) of 29 patients with pulmonary infections, (2 mg/mL) of P. aeruginosa at this institution and because aminoglycosides are commonly used to treat proven or suswhile the microbiologic cure rate in this population was 40% (5 of 13), reflecting a low rate of definitive bacteriologic diagpected infections caused by this organism.
Another reason for using this dose, aside from optimizing nosis. Length of therapy was similar between ODA and traditional dosing regimens. bacterial eradication, is to decrease toxicity due to saturation of the capacity-limited tissue-uptake mechanism for aminoglyAs a result of the ODA program implementation, annual hospital savings in excess of $100,000 (U.S.) are being realized cosides [33] . It is likely that a 5-mg/kg dose would also saturate the uptake mechanism; however, if that is true, no additional because of decreased supply and labor costs, less frequent determinations of serum drug concentrations, and decreased toxicity would result from the higher dose since tissue accumulation would be at a maximum. While the 5-mg/kg dose would nephrotoxicity [55, 56] . likely result in the same degree of toxicity, it may not achieve optimum peak-to-MIC ratios. Summary It can be argued that aminoglycosides are usually used in combination with other antibiotics such as b-lactams and that
The pharmacodynamics of aminoglycosides have been it is not necessary to optimize the aminoglycoside dose. This shown to be maximized when high-dose, extended-interval may be true but is somewhat speculative. The approach with aminoglycoside therapy is employed. As a result, the impleuse of a 7-mg/kg dose is more conservative in that it considers mentation of such a program should optimize potential for the worst-case scenario and doses accordingly.
clinical cure and minimize toxicity, and it may help to prevent ODA therapy has been used for many types of infections, the development of resistance. Although such dosing is not including intraabdominal, pulmonary, genitourinary, skin, and appropriate for all patients, this strategy appears to be useful soft tissue, as well as staphylococcal and streptococcal endocarin the majority of patients requiring aminoglycoside therapy ditis. According to program criteria at Hartford Hospital, ODA and can be successfully employed as a hospital-wide program. therapy is not administered to adult patients with ascites, paWith most programs, provisions must be made for physicians tients with burns over ú20% of their body surface area, pregto deviate from the general program when the needs of the nant patients, those on dialysis for end-stage renal disease, or patient so dictate. patients with enterococcal endocarditis. Immunocompromised patients are not excluded from receiving ODA.
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